← All candidates
Eight insider buys in the last year — $1.42M in all.
22 filings on record.
MEDMEDIFAST INC
NYSE · Consumer Cyclical · $133.72M
$11.96
-0.25% · Sep 16
Eight insider buys in the last year — $1.42M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 8 buys◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$133.72M
Float
8.4M
75% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
0.4
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Kiai Parsa
Bought $514.7K on Aug 26 — 41,975 sh @ $12.26, held indirect, 5.9% of their stake.
No completed positions to measure
Chairman & CEO
Chard Daniel R
Bought $5.0K on Jun 13 — 381 sh @ $13.13, held indirect, 0.3% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
3 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
17 more transactions on Pro →Context
Wall St
$12.00 avg target
+0.3% vs today · 1 analyst
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q2 '26−$0.28 act+$0.37
Q1 '26−$0.19 act+$0.33
Q4 '25−$1.65 act−$0.83
Q3 '25−$0.21 act+$0.15
Coverage
The file stays open
22 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice